Eli Lilly & Co), albiglutide (Tanzeum, GlaskoSmithKline), and semaglutide (Ozempic, Novo Nordisk) [878]
Diabetes Care 2019;42:227281
Without structured support, these changes can make weight maintenance challenging
Abdelmalek, Lidija Covic, Athan Kuliopulos JHEP Reports .2026
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities
Glycocalyx function Regulating vascular permeability Notably, glycocalyx degradation exacerbates vascular permeability by disrupting VE-cadherin and occludin [41], while intact glycocalyx suppresses MMP-9-mediated inflammation [42, 43]